NCT06458374 ATTR Cardiac Amyloidosis in a Selected Population
| NCT ID | NCT06458374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helse Møre og Romsdal HF |
| Condition | ATTR Amyloidosis Wild Type |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2034-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-09-01 with a primary completion date of 2034-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.
Eligibility Criteria
Inclusion Criteria: * Male \> 50 years * Female \> 60 years * operated CTS at Ålesund Hospital Exclusion Criteria: * not consented * do not speak Norwegian * secondary cause of CTS as traumatic or rheumatic * cannot be followed \> 5 years due to other medical conditions * Cardiac disease at time of operation for CTS
Contact & Investigator
Torstein Hole, MD, PhD
PRINCIPAL INVESTIGATOR
Helse Møre og Romsdal HF and NTNU
Frequently Asked Questions
Who can join the NCT06458374 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying ATTR Amyloidosis Wild Type. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06458374 currently recruiting?
Yes, NCT06458374 is actively recruiting participants. Contact the research team at torstein.hole@helse-mr.no for enrollment information.
Where is the NCT06458374 trial being conducted?
This trial is being conducted at Ålesund, Norway.
Who is sponsoring the NCT06458374 clinical trial?
NCT06458374 is sponsored by Helse Møre og Romsdal HF. The principal investigator is Torstein Hole, MD, PhD at Helse Møre og Romsdal HF and NTNU. The trial plans to enroll 180 participants.